Drug Profile
Tadalafil/tamsulosin - Hanmi Pharmaceutical
Alternative Names: Gugutams cap.; HCP 1303Latest Information Update: 09 Nov 2018
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Amines; Benzene derivatives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Ethers; Indoles; Pyridones; Small molecules; Sulfonamides; Vasodilators
- Mechanism of Action Alpha-1a adrenergic receptor antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Benign prostatic hyperplasia; Erectile dysfunction
Most Recent Events
- 09 Nov 2018 Chemical structure information added
- 01 May 2016 Hanmi Pharmaceutical completes a phase-III clinical trial in Benign prostatic hyperplasia in South Korea (PO) (NCT02667938)
- 09 Oct 2015 Phase-III clinical trials in Erectile dysfunction in South Korea (PO)